The National Medical Products Administration conditionally approves the listing of Anda Aatinib Capsules.

Recently, the National Medical Products Administration approved the application of Anshi Pharmaceutical Co., Ltd. for the conditional approval of the first-in-class innovative drug Bendamustine capsules through priority review and approval process. The drug is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer who have previously undergone platinum-based chemotherapy and experienced disease progression during or after treatment, or are intolerant to platinum-based chemotherapy, and have been confirmed by testing to have an exon 20 insertion mutation in the epidermal growth factor receptor. The approval of this drug provides a new treatment option for patients.